Is Phathom Pharmaceuticals Inc (PHAT) overvalued? · rev $55.3M
Phathom Pharmaceuticals Inc (PHAT) is a biotechnology company listed on US.
This page asks whether Phathom Pharmaceuticals Inc (PHAT) looks expensive on cached numbers — not a short thesis.
Latest reported PHAT revenue for 2024-12-31 was $55.3M. Net income was -$334.3M. Revenue was up 8001.5% from 2023-12-31 to 2024-12-31. PHAT currently screens at market cap $622.7M.
PHAT currently screens at market cap $622.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PHAT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PHAT stock page for the full model, not this heading.
Not investment advice.